CGRP mAb Subcutaneous denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issued an Experimental/Investigational Denial for Your CGRP Monoclonal Antibody

An experimental or investigational denial from UnitedHealthcare means UHC's medical policy review concluded that the drug or specific use does not yet meet the plan's evidence standard for coverage as an established treatment. For FDA-approved CGRP monoclonal antibodies used for their labeled indications, this determination is usually either a factual error — particularly if the FDA approval is recent — or reflects use in a population or diagnosis that falls outside the approved label. UHC updates its medical policies on a published cycle, and a newly approved indication may not yet be reflected in the version of the policy that was applied to your claim.

## Why This Denial Is Appealable

Federal law and UHC's own appeals process require that a coverage denial based on experimental status be evaluated against current medical evidence and FDA approval status. If the prescribed use carries FDA approval, the experimental denial is factually unsupportable and should be reversed on internal appeal when you submit the FDA prescribing label. If the use is off-label, the appeal must demonstrate that the use is documented in peer-reviewed literature and recognized by a relevant professional society guideline — UHC's medical policies for oncology and some specialty drugs explicitly permit coverage of off-label uses meeting this evidentiary bar, and the same argument may apply here under the plan's general off-label coverage policy.

## Your Federal Appeal Rights

• ACA §2719 external review is your most powerful tool on experimental denials: the independent reviewer applies an objective evidence standard, not UHC's internal policy criteria, and must assess whether the denial is consistent with generally accepted medical practice.
• ERISA §503 governs self-funded plans; UHC must provide a written, evidence-based rationale for the experimental determination and allow a meaningful internal appeal.
• The external-review window is generally approximately four months after final internal denial — submit your internal appeal promptly.
• Expedited review is available if your condition creates clinical urgency.

## Documentation to Gather

• FDA approval documentation: the current FDA prescribing label from DailyMed confirming the approved indication; highlight the specific indication matching your diagnosis. Include as a numbered exhibit.
• UHC's medical policy: download the current UHC medical policy for CGRP antagonists from uhcprovider.com; identify the exact experimental-coverage criteria and demonstrate your case does not meet them.
• Professional society guideline endorsement: a citation (author/organization/year) from the relevant specialty guideline body — such as the American Headache Society or applicable neurology organization — establishing that this drug class is the standard of care for your indication. Obtain the exact current language.
• Prescriber medical-necessity letter: must state the FDA-approved indication, reference the guideline, address the experimental criteria point by point, and confirm the treatment is accepted standard of care.
• Clinical history: chart notes documenting diagnosis, prior treatment failures, and current severity to contextualize medical necessity alongside the experimental-status rebuttal.

## Criteria-Mapping Structure

| UHC Experimental Criterion | Rebuttal | |---|---| | Not FDA-approved for submitted indication | FDA label excerpt, DailyMed link, approval date | | Insufficient published evidence | Applicable guideline organization citation; prescriber letter on standard-of-care consensus | | Not recognized by qualified experts | Prescriber specialty credentials + letter citing professional society position | | Policy not yet updated to reflect new approval | Request UHC apply current FDA status; cite effective date of FDA approval vs. policy review date |

Always obtain the most current version of UHC's CGRP medical policy and the current FDA label before submitting — both are updated periodically and your appeal must respond to the versions in effect at the time of denial.